Holen Sie sich die Stockscreener-App
321.71
0.16%
-0.52
Handel nachbörslich:
321.71
Schlusskurs vom Vortag:
$322.23
Offen:
$321.88
24-Stunden-Volumen:
345.79K
Relative Volume:
0.56
Marktkapitalisierung:
$12.65B
Einnahmen:
$1.40B
Nettoeinkommen (Verlust:
$177.69M
KGV:
71.12
EPS:
4.5234
Netto-Cashflow:
$174.93M
1W Leistung:
-0.91%
1M Leistung:
-2.44%
6M Leistung:
+15.03%
1J Leistung:
+8.20%
1-Tages-Spanne:
$321.38
$323.07
1-Wochen-Bereich:
$321.38
$326.43
52-Wochen-Spanne:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
321.71 | 12.67B | 1.40B | 177.69M | 174.93M | 4.5234 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-11-18 | Eingeleitet | Wells Fargo | Underweight |
| 2025-10-08 | Hochstufung | Needham | Hold → Buy |
| 2025-09-02 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Penumbra, Inc. Reports Third Quarter 2025 Financial Results - Quantisnow
Penumbra Shareholders Approve Merger with Boston Scientific - The Globe and Mail
Penumbra revenue up 15.6% to USD 374.8M in Q1 2026 - Medical Buyer
PEN Maintained by Citigroup -- Price Target Lowered to $350 - GuruFocus
Penumbra (PEN) Margin Expansion To 11.8% Tests Bulls High P E Narrative - Sahm
Citi Maintains Penumbra(PEN.US) With Hold Rating, Cuts Target Price to $350 - Moomoo
Penumbra Is Maintained at Outperform by Evercore ISI Group - Moomoo
Liquidity Mapping Around (PEN) Price Events - Stock Traders Daily
PEN Maintained by Evercore ISI Group -- Price Target Lowered to $335 - GuruFocus
Penumbra Is a 'Strong' Strategic Fit for Boston Scientific, RBC Says - Moomoo
Penumbra shareholders approve merger with Boston Scientific By Investing.com - Investing.com Australia
Penumbra, Inc. Q1 2026 Financial Results: Earnings, Comprehensive Income, and Stockholders’ Equity Highlights - Minichart
Penumbra IncStockholders approve merger with Boston ScientificSEC filing - marketscreener.com
Penumbra shareholders approve merger with Boston Scientific - Investing.com
Penumbra (NYSE: PEN) shareholders approve Merger Proposal; closing conditions remain - Stock Titan
Penumbra (NYSE: PEN) investors back merger, await antitrust approvals - Stock Titan
Evercore Maintains Penumbra(PEN.US) With Buy Rating, Cuts Target Price to $335 - Moomoo
Penumbra: Q1 Earnings Snapshot - theheraldreview.com
Assessing Penumbra (PEN) Valuation As Growth Expectations Meet A Premium P/E Multiple - Yahoo Finance
PEN Stock Price, Quote & Chart | PENUMBRA INC (NYSE:PEN) - ChartMill
Penumbra Shareholder Notice - TMX Newsfile
MSN Money - MSN
Penumbra (PEN) Misses Q1 Earnings Estimates - Yahoo Finance
[10-Q] Penumbra Inc Quarterly Earnings Report - Stock Titan
Earnings Flash (PEN) Penumbra, Inc. Reports Q1 Revenue $374.8M, vs. FactSet Est of $371.3M - marketscreener.com
Penumbra (NYSE: PEN) posts $374.8M Q1 2026 revenue as Boston Scientific deal looms - Stock Titan
Penumbra posts $32.6M profit as Boston Scientific deal halts outlook - Stock Titan
Penumbra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PEN Technical Analysis | Trend, Signals & Chart Patterns | PENUMBRA INC (NYSE:PEN) - ChartMill
Penumbra earnings in focus as Boston Scientific deal looms By Investing.com - Investing.com South Africa
Penumbra earnings in focus as Boston Scientific deal looms - Investing.com
Penumbra, Inc. (PEN) Stock Analysis: A 12.44% Potential Upside in the Thriving Medical Devices Sector - DirectorsTalk Interviews
Vanguard Group Inc. Cuts Stock Position in Penumbra, Inc. $PEN - MarketBeat
Inside Boston Scientific's $15 billion offer for Alameda's largest employer - The Business Journals
Penumbra, Inc. (NYSE:PEN) Sees Large Drop in Short Interest - MarketBeat
Vanguard Capital Management (NYSE: PEN) holds 1.99M shares, 5.07% stake - Stock Titan
[ARS] Penumbra Inc SEC Filing - Stock Titan
Penumbra (PEN) down 1.6% since last earnings report: Can it rebound? - MSN
Penumbra (NYSE: PEN) outlines 2026 meeting and $14.5B Boston Scientific sale - Stock Titan
Teacher Retirement System of Texas Reduces Stake in Penumbra, Inc. $PEN - MarketBeat
3 Reasons Why Penumbra (PEN) Is a Great Growth Stock - Yahoo Finance
Investor Outlook: Penumbra, Inc. (PEN) Eyes 10.88% Upside With Strong Revenue Growth - DirectorsTalk Interviews
A Look At Penumbra (PEN) Valuation After Positive STORM PE Trial Outcomes - Sahm
Why (PEN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
How STORM-PE Thrombectomy Results and Lightning Flash Data Will Impact Penumbra (PEN) Investors - simplywall.st
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):